IP Library Granted Patent US 7,455,987
Granted Patent B1
US 7,455,987 · App. 09/664,326 · Granted Nov 25, 2008

Signal sequences for preparing leu-hirudin by secretion by

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,455,987
App. No.
09/664,326
Granted
Nov 25, 2008
Kind
B1
Abstract

The present invention relates to a efficient expression of a protein, particularly, hirudin; a protein precursor comprising a signal sequence and the sequence of aa X -hirudin, wherein aa X is a selected amino acid, and aa X is preferably leucine; to its preparation and use; and to processes for finding signal sequences for secretory expression of any desired protein in E coli ; and to processes for the secretory expression of any desired protein in E coli.

Claims (8)

1. A process for selecting a signal peptide for secretory expression of a desired hirudin or hirudin derivative protein in E. coli , comprising:

(a) expressing in E. coli in culture medium, hirudin or a hirudin derivative which has antithrombotic activity, and which has a defined amino acid, aa x , at its N terminus, wherein said amino acid is connected via its N-terminal to a test signal peptide;

(b) determining expression rate by measuring said hirudin or hirudin derivative activity in the culture supernatant;

(c) repeating steps (a) and (b) with various signal peptides;

(d) selecting said signal peptide by comparing the expression rates represented by the hirudin or hirudin derivative antithrombotic activity found in step (b) wherein the E. coli bacteria are not E. coli secretor mutants.

2. The process of claim 1 , wherein aa X is leucine.

3. The process of claim 1 , further comprising expressing said signal peptide and the desired hirudin or hirudin derivative protein in E. coli via a nucleic acid construct, wherein expression of the desired hirudin or hirudin derivative protein and said signal peptide occurs with simultaneous elimination of said signal peptide wherein the E. coli bacteria are not E. coli secretor mutants.

4. The process of claim 1 , wherein the desired hirudin or hirudin derivative protein is hirudin.

Assignments (2)
CHANGE OF NAME Recorded Nov 22, 2005
From: AVENTIS PHARMA DEUTSCHLAND GMBH
To: SANOFI-AVENTIS DEUTSCHLAND GMBH
Reel/Frame 016800/0538 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 21, 2001
From: HABERMANN, PAUL; BENDER, RUDOLF
To: AVENTIS PHARMA DEUTSCHLAND GMBH
Reel/Frame 011611/0965 →